ArthNow Logo
ArthNow
•3 min read•
✦Reported by Moneycontrol

Tata Trust approves Rs 50-crore grant to Pune's Jehangir Hospital as part of Rs 150-crore-plus funding

Tata Trust approves Rs 50-crore grant to Pune's Jehangir Hospital as part of Rs 150-crore-plus funding
Source: Moneycontrol

Executive Brief • Key Highlights

Fast factual intelligence distilled for busy investors, executives, and answer bots:

  • ✓The Sir Dorabji Tata Trust approved over Rs 150 crore in grants, including Rs 50 crore for Pune’s Jehangir Hospital.
  • ✓The hospital plans a major expansion to add more beds.
  • ✓A source said there is "no conflict of interest" regarding the funding.

Story at a Glance

Category
Indian Markets
Reported By
Moneycontrol
Reading Speed
3 Minute(s)
Market Focus
India Economy

The Sir Dorabji Tata Trust approved over Rs 150 crore in grants to five initiatives, including Rs 50 crore to a hospital in Pune led by Jehangir H C Jehangir, who has been associated with other Tata Trusts.

All the proposals at the meeting chaired by Tata Trusts chairman Noel Tata, and also attended by Venu Srinivasan and Vijay Singh, people aware of the matter said.

There was no discussion at the meeting on any of the other issues within the Tata group dominating the headlines, they said.

Amid questions raised over a grant being made to an entity with whom Jehangir, a trustee of the Sir Ratan Tata Trusts, is associated, a source asserted that there is "no conflict of interest" in this case.

🔒
Premium Content

Unlock the Full Story with ArthNow Premium

To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.

✓ Full Unabridged Reports✓ Executive Audio Briefs✓ 100% Ad-Free Reading
Verified Publication Source

Moneycontrol

Read the full, original unfiltered story directly on the publisher's portal.

Visit Original Article

This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.